Trump Misleads the Nation Yet Again About COVID-19 Miracle Cure

With the Republican convention imminent, President Trump wants some good news. So he bullied the FDA into issuing an emergency approval for a COVID-19 treatment:

Calling it “a truly historic announcement,” U.S. President Donald Trump on Sunday hailed a federal government emergency authorization for use of convalescent blood plasma that he declared would “save countless lives” of coronavirus patients.

Trump and his health secretary, Alex Azar, at a briefing for reporters, noted a 35% decrease in mortality among those younger than 80 who were not on a respirator, a month after receiving the treatment early in the course of their disease. “We dream in drug development of something like a 35% mortality reduction,” Azar, the secretary of Health and Human Services, said alongside the president.

A “senior administration official” expanded on this:

If you’re one of the 35 people out of a hundred who survive severe COVID symptoms because of convalescent plasma, this is certainly a breakthrough,” the official said.

Ahem. The treatment involves infusing patients with blood plasma from people who have recovered from COVID-19. This is very much a legitimate line of research, but it most certainly doesn’t save 35 lives out of a hundred or anything close to it. I know you count on me for chart-based versions of data like this, so here you go:

Among a subset of seriously ill patients, researchers produced several preliminary results:

  • 7-day mortality. Survival rates were about 3 percentage points better with the plasma treatment if transfusion was done quickly after diagnosis.
  • 30-day mortality. Survival rates were about 5 percentage points better with the plasma treatment if transfusion was done quickly after diagnosis.
  • 7-day mortality with high IgG plasma vs. low IgG plasma. Survival rates were about 5 points better with high IgG plasma.
  • 30-day mortality with high IgG plasma vs. low IgG plasma. Survival rates were about 7 points better with high IgG plasma.

Needless to say, none of these are anywhere close to what most people think of when they hear about a 35 percent difference. So where did that come from? Well, if you cherry pick one of the results—7-day high vs. low—and calculate the death rate instead of the survival rate, you get 8.9 divided by 13.7. This equals 0.65, which means the high-plasma group died at a rate 35 percent lower than the low plasma group on a relative basis. This is a number that might be of importance to a researcher or a statistician, but not to anyone else. For the lay public, the basic result is that plasma treatment might improve your survival rate by four or five percentage points.

In other words, the plasma treatment is promising but unlikely to make a huge difference. It’s certainly light years away from “historic” and in no way does it save 35 lives out of a hundred. Four or five is more like it. Nonetheless, Trump implied tremendous results; Azar confirmed it; FDA commissioner Stephen Hahn stayed silent; and a senior administration official then retailed an even more ridiculous version of the whole thing.

None of this was an accident. It was carefully designed to mislead the lay public into thinking that Trump had decisively ripped a miracle treatment out of the hands of the stupid doctors and made it available to everyone. He didn’t. Tens of thousands of people have already received plasma treatment and that will continue with little change. Eventually more careful studies will be done and we’ll have a better idea of just how well this treatment really works. In the meantime, as usual, never listen to anything that Donald Trump says about it.

WE'LL BE BLUNT:

We need to start raising significantly more in donations from our online community of readers, especially from those who read Mother Jones regularly but have never decided to pitch in because you figured others always will. We also need long-time and new donors, everyone, to keep showing up for us.

In "It's Not a Crisis. This Is the New Normal," we explain, as matter-of-factly as we can, what exactly our finances look like, how brutal it is to sustain quality journalism right now, what makes Mother Jones different than most of the news out there, and why support from readers is the only thing that keeps us going. Despite the challenges, we're optimistic we can increase the share of online readers who decide to donate—starting with hitting an ambitious $300,000 goal in just three weeks to make sure we can finish our fiscal year break-even in the coming months.

Please learn more about how Mother Jones works and our 47-year history of doing nonprofit journalism that you don't find elsewhere—and help us do it with a donation if you can. We've already cut expenses and hitting our online goal is critical right now.

payment methods

WE'LL BE BLUNT

We need to start raising significantly more in donations from our online community of readers, especially from those who read Mother Jones regularly but have never decided to pitch in because you figured others always will. We also need long-time and new donors, everyone, to keep showing up for us.

In "It's Not a Crisis. This Is the New Normal," we explain, as matter-of-factly as we can, what exactly our finances look like, how brutal it is to sustain quality journalism right now, what makes Mother Jones different than most of the news out there, and why support from readers is the only thing that keeps us going. Despite the challenges, we're optimistic we can increase the share of online readers who decide to donate—starting with hitting an ambitious $300,000 goal in just three weeks to make sure we can finish our fiscal year break-even in the coming months.

Please learn more about how Mother Jones works and our 47-year history of doing nonprofit journalism that you don't elsewhere—and help us do it with a donation if you can. We've already cut expenses and hitting our online goal is critical right now.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate